PFIZER INC
PFENYSETrading Snapshot
- Day Range
- $27.36 β $28.11
- 52-Week Range
- $23.62 β $31.44
- Volume (shares)
- 38,285,319
- Avg Volume (shares)
- β
- Shares Outstanding
- 5.70B
- Next Earnings
- 2027-02-02
Fundamentals Snapshot
- Annual Revenue
- $62.58B
- Last Q Revenue
- $16.58B
- P/E Ratio
- 38.9
- P/S Ratio
- 2.5x
- EPS (TTM)
- $0.70
- Dividend Yield
- 6.24%
- Dilution (1yr)
- β0.3%
PFIZER INC
PFEAbout PFIZER INC
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

4 High-Yield Dividend Stocks Retirees Should Think Twice About Owning
Yields of 5% to 6.3% look like a gift when the S&P 500 barely pays 1%. But four household names are sending signals that a retiree's income check may not be as safe as the number suggests.

Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?
Johnson & Johnson maintains a diversified business model balancing pharmaceutical innovation with a massive medical technology segment. Pfizer is undergoing a significant transition by investing heavily in oncology and o

5 Dividend Stocks Yielding Over 4% Retirees Should Buy Before December
Retirees heading into year-end need two things from an income stock: a yield that tops inflation and a payout the business can comfortably fund. A big headline yield can also be the market pricing in a cut, which is the

Breakfast News: When Tech Wobbles, Dividends Pay
Motley Fool analysts share their favorite dividend stocks as tech stocks wobble.

Pfizer's Launched and Acquired Drugs Grew 32% in Q3 β and 3 Other Reasons to Buy the Stock Before 2027
Pfizer is a well-respected drugmaker facing typical industry headwinds. The company is financially strong, and new drug development is slowly gaining traction.

Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects?
Lilly and Pfizer offer contrasting growth stories driven by blockbuster drugs, expanding pipelines and strategic investments.